One donor cornea, 400 implants: the graft shortage starts looking like a factory problem

A single human donor cornea has been expanded into a cell bank large enough to fabricate more than 400 implants, according to Precise Bio's chief executive, and the resulting printed tissue is now in a Phase I trial testing safety in patients ^[11][5][15]. If that ratio survives the clinic, corneal supply stops being a bereavement-and-logistics problem and becomes a manufacturing problem, where the binding constraints are batch release, capacity and cost rather than how many people die in a usable state within a few hours of a recovery team ^[7].

Live Science reports that last year a patient received the first corneal implant made solely of human cells grown in a lab ^[1]. The technology comes from Precise Bio, an Israeli regenerative medicine company also based in North Carolina, and produces a transparent, layered structure meant to resemble a healthy cornea ^[3][4]. Corneal grafts replace the clear dome at the front of the eye and are used for severe scarring and inflammation, eye injuries and complications from eye surgery ^[6].

Anthony Atala, a company co-founder who directs the Wake Forest Institute for Regenerative Medicine, describes the current pipeline: tissue recovered from deceased donors within a few hours of death, banked, screened and tested, then preserved and implanted usually within a couple of weeks ^[15][7]. Every step is scheduled around an event nobody planned. Atala says availability is the major limitation, with very limited donor supply and a significant worldwide shortage ^[8].

Chief executive Aryeh Batt puts figures on the gap: roughly 70 people worldwide remain without a cornea for every transplant performed, and 12 million to 15 million people who need a graft cannot get donor tissue ^[9][10]. On his own ratio, the system serves about 1.4 percent of the patients in front of it ^[16]. Read the other way, 400 implants per donor cornea implies roughly 30,000 donor corneas to cover 12 million patients ^[17]. Thirty thousand starting tissues plus a manufacturing plant is a supply chain a planner can actually model; 12 million donors is not.

Two further company claims are operational rather than clinical. Batt says the tissue was engineered with mechanical properties that make it easier to implant than donor tissue and shorten operating times ^[12]. He also says printed tissue reaches over 4,000 cells per square millimetre against about 2,000 to 2,500 for standard donor tissue, which he expects to produce a superior optical outcome ^[13]; that is at least 1.6 times the density at the top of the donor range ^[18]. Live Science's editors attach a caveat: the ease-of-surgery and cell-density results come from laboratory and animal studies, human trials are still running, and claims that the printed tissue performs better than donor tissue remain unconfirmed ^[14].

What to watch. Phase I is a safety readout, not an answer on optics or graft survival ^[5]. The material available does not give trial size, sites or timelines, so treat the 400-per-donor figure as a company statement about process capability rather than a demonstrated yield after release testing and rejects ^[11]. For eye banks and transplant programmes, the planning question is whether their role migrates from moving screened tissue inside a two-week window to sourcing and qualifying starting material for a manufacturer, which is a different set of contracts, consent language and quality obligations ^[7].